What are probiotic strains?

What are probiotic strains?

What are probiotic strains?

Probiotics have many genera, species and strains. For example, the common bifidobacterium lactis belongs to a genus of probiotics. It’s these strains that can really play a role. Strains are different individuals separated by scientists from probiotics. They have different effects on our body, such as improving digestion, enhancing immunity and lowering cholesterol levels.

In recent years scientific researchers have confirmed that the functions and benefits of probiotics are “strain specific” and “dosage dependent”. In other words, just because 1 strain has a certain function or therapeutic effect doesn’t mean all the probiotics in the genus or species have the function or therapeutic effect; the dosage needed for a strain to take effect is also different for different strains, and even the same strain needs different dosages to take effect for different diseases.

For example, the results of clinical tests show that lactobacillus acidophilus NCFM® can significantly lower the carcinogenic enzyme level in colon cancer patients, but there is no way to infer that other lactobacillus acidophilus strains also have the same function. The same is true for other bacteria. Different strains of bacteria may be the same in appearance, but their biological properties can be different.

The DuPont portfolio includes the HOWARU® brand of highly effective probiotic single strains and preformulated blends. Each product in the HOWARU® lineup is proven efficacious through multiple human clinical studies.

HOWARU® single strain:

Commercial name Taxonomy Strain designation Concentration*
HOWARU® Dophilus Lactobacillus acidophilus NCFM® 200B CFU/gm
HOWARU® Transit (Bifido) Bifidobacterium lactis HN019™ 300B CFU/gm
HOWARU® Protect EarlyLife (Rhamnosus) Lactobacillus rhamnosus HN001™ 450B CFU/gm

* Billion or 109 CFU

HOWARU® Dophilus
Based on lactobacillus acidophilus NCFM®

Lactobacillus acidophilus is a genus of gram-positive, non-spore-forming, homofermentative, and catalase-negative rod-shaped bacteria. It is a bacterium commonly found in the human intestine, mouth and vagina. In addition to traditional fermented dairy products (e.g. kefir), it is also widely used in probiotic foods and dietary supplements.

Back in the 1970s, people isolated HOWARU® Dophilus (lactobacillus acidophilus NCFM®) from the human intestine, which could be safely used in the food industry, for the first time. It was also the world’s first lactobacillus acidophilus used in health foods. DuPont used the phenotype and genotype methods to confirm that lactobacillus acidophilus NCFM® is a true Type A1 lactobacillus acidophilus. The name NCFM® is derived from an abbreviation of the “North Carolina Food Microbiology”, which is the name of the research laboratory at the North Carolina State University (NCSU) where the strain was first discovered. This strain is deposited with the American Type Culture Collection where it has the number ATCC 700396 (ATCC Safe Deposit SD5221).

HOWARU® Transit (Bifido)
Based on Bifidobacterium lactis HN019™

Bifidobacterium lactis HN019™ was originally isolated from a yogurt produced in New Zealand and has been consumed as part of dairy products for a long time. It is the fruit of a 5 year research project conducted by the New Zealand Milk and Health Research Centre, the New Zealand Dairy Research Institute and other internationally renowned health researchers. The researchers screened more than 2,000 strains of lactobacilli and bifidobacteria for potential probiotic candidates. Bifidobacterium lactis HN019™was considered to have the best probiotic potential based on its ability to resist bile and low pH in vitro. The strain has been deposited with the Australian Government Analytical Laboratories (AGAL) as deposit number NM97/09513.

HOWARU® Protect Earlylife (Rhamnosus)
Based on lactobacillus rhamnosus HN001™

Lactobacillus rhamnosus HN001™ was originally isolated from cheddar cheese produced in New Zealand and has been consumed as part of dairy products for more than 20 years. After the New Zealand Dairy Research Institute had screened 200 strains, Lactobacillus rhamnosus HN001™ was identified as the potential probiotic strain, and was used for further animal and human studies as it could survive at a low pH and a relatively high bile concentration. The studies show that Lactobacillus rhamnosus HN001™ meets the most rigorous requirements for probiotic properties. Besides, the strain’s ability to enhance immunity received close attention and was recorded in several studies. The strain has been deposited with the Australian Government Analytical Laboratories (AGAL) as deposit number NM97/09514.

The system checks that you are in Mainland China. Do you want to switch to the Chinese version?